Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Just an out of PTSC touch thought...

Further to optymystic's point, even if there were a huge cash influx, I'd prefer, and I think it's most prudent to acquire using shares, and preserve the cash. You never know what opportunities tomorrow holds, and more cash will give RG MORE OPTIONS, IMO. So even if the 10K showed a $50M quarter, I'd say do the deal just as structured, because the extra cash will boost the share price, and in turn lower the amount of shares needed in the deal AND still leave them the cash to pursue Aquisition 2 Corp., and Acquisition 3 Corp., etc. etc. etc.



OK...I'll stop pumping now as I don't want to get flagged.

Share
New Message
Please login to post a reply